The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Jun. 29, 8:41 AM

Slide #4. Cascadian Therapeutics, Inc. Secondary Offering

Company: Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Date announced: 6/23/2016
Shares Offered: 17,250
Date of Pricing: 6/23/2016
Price Per Share: $800.00
Secondary Offering Details: Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced the pricing of the previously announced underwritten offering of 35,000,000 shares of its common stock at a price to the public of $0.80 per share, for expected gross proceeds of $28.0 million. As part of the common stock offering, Cascadian Therapeutics granted the underwriters a 30-day option to purchase 5,250,000 additional shares of Cascadian Therapeutics common stock. In addition, Cascadian Therapeutics agreed to sell 17,250 shares of its Series D Convertible Preferred Stock at a price of $800.00 per share directly to affiliates of BVF Partners L.P., which are existing stockholders and affiliates of a member of the board of directors of Cascadian Therapeutics, for expected gross proceeds of $13.8 million

Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. Co.'s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. Co. also develops preclinical product candidates in oncology, and potentially certain rare diseases, using its acquired protocell technology. Co. also collaborates with partners to discover and develop additional product candidates.

CASC SEC Filing Email Alerts Service

Open the CASC Page at The Online Investor »

Company Name:  Cascadian Therapeutics Inc
Website:  www.oncothyreon.com
Sector:  Biotechnology
Number of ETFs Holding CASC:  15
Total Market Value Held by ETFs:  $3.33M
Total Market Capitalization:  $87.00M
% of Market Cap. Held by ETFs:  3.83%
 

Open the CASC Page at The Online Investor (in a new window) »

June 29, 2016    8:41 AM Eastern
Quotes delayed 20 minutes



Buy (3.25 out of 4)
57th percentile
(ranked higher than approx. 57% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.